Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- UK’s Clinigen Launches Japan Operations with Takeover of Foscavir
October 19, 2016
- Kaketsuken Denies Unauthorized Manufacturing or Cover-up, Blames Ambiguity in Approval Doc
October 19, 2016
- Entyvio’s Real-World Data Support Trial Results: Takeda
October 18, 2016
- Ethical Drug Sales Up 2.7% in August: Crecon Report
October 18, 2016
- JT Grants S. Korea Rights for Anemia Drug to JW Pharmaceutical
October 17, 2016
- PDUFA Date for COPD Drug Set for May 29, 2017: Sunovion
October 17, 2016
- Sandoz Will Outpace Generic Market Growth: New Japan Chief
October 14, 2016
- Gilead Japan Trying to Dig Up Untreated Hep C Patients as Demand Ebbs
October 14, 2016
- Mark Tennyson to Take Helm of Amgen Astellas BioPharma
October 14, 2016
- Daiichi Sankyo, Dana-Farber Link Up on Lung Cancer Preclinical Research
October 14, 2016
- Gilead Japan Eyes Cancer, Inflammatory Disease Meds to Raise Profile as Specialty Pharma
October 13, 2016
- Patient Enrollment for Tepotinib PII Begins in Japan: Merck Serono
October 13, 2016
- 69.2% Response Rate Seen in Lenvatinib, Pembrolizumab Combination: Eisai
October 13, 2016
- Daiichi Sankyo Kicks Off Quizartinib Global PIII for 1st-Line AML
October 13, 2016
- Takeda to Tighten R&D Focus, Strengthen Collaboration with Outside Parties; Main Challenge Will Be Financial
October 13, 2016
- Pfizer’s Cancer Research Selected for Feasibility Study under AMED Program; Applied Jointly with Mie Univ. and Other Partners
October 13, 2016
- Interview: Teva Exec Says Takeda JV Can Grow Profit despite Generic Price Declines
October 12, 2016
- Takeda, UK’s Crescendo Cut Collaboration Deal on Cancer Therapeutics
October 12, 2016
- Daiichi Sankyo’s ADC DS-8201a Well-Tolerated in PI
October 12, 2016
- There Will Be Consolidation in Japan Generic Space: Teva Exec
October 11, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…